JP2004533428A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004533428A5 JP2004533428A5 JP2002579423A JP2002579423A JP2004533428A5 JP 2004533428 A5 JP2004533428 A5 JP 2004533428A5 JP 2002579423 A JP2002579423 A JP 2002579423A JP 2002579423 A JP2002579423 A JP 2002579423A JP 2004533428 A5 JP2004533428 A5 JP 2004533428A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halogen
- con
- substituents
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 25
- 229910052736 halogen Inorganic materials 0.000 claims 18
- -1 = X Inorganic materials 0.000 claims 17
- 125000001424 substituent group Chemical group 0.000 claims 16
- 150000002367 halogens Chemical class 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 5
- 125000003282 alkyl amino group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 125000006413 ring segment Chemical group 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 3
- HCUOEKSZWPGJIM-IYNMRSRQSA-N (e,2z)-2-hydroxyimino-6-methoxy-4-methyl-5-nitrohex-3-enamide Chemical compound COCC([N+]([O-])=O)\C(C)=C\C(=N\O)\C(N)=O HCUOEKSZWPGJIM-IYNMRSRQSA-N 0.000 claims 2
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 239000000470 constituent Substances 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 2
- 125000006091 1,3-dioxolane group Chemical group 0.000 claims 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000005059 halophenyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000003367 polycyclic group Chemical group 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0108591.9 | 2001-04-05 | ||
| GBGB0108591.9A GB0108591D0 (en) | 2001-04-05 | 2001-04-05 | Therapeutic agents |
| PCT/GB2001/003741 WO2002081435A1 (en) | 2001-04-05 | 2001-08-21 | Sulphones which modulate the action of gamma secretase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004533428A JP2004533428A (ja) | 2004-11-04 |
| JP2004533428A5 true JP2004533428A5 (cg-RX-API-DMAC7.html) | 2012-03-15 |
| JP5113976B2 JP5113976B2 (ja) | 2013-01-09 |
Family
ID=9912329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002579423A Expired - Fee Related JP5113976B2 (ja) | 2001-04-05 | 2001-08-21 | γ−セクレターゼの作用を調節するスルホン |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20040116404A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1379498B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5113976B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE498608T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2001279971B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2442882C (cg-RX-API-DMAC7.html) |
| DE (1) | DE60144064D1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2359388T3 (cg-RX-API-DMAC7.html) |
| GB (1) | GB0108591D0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002081435A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0108591D0 (en) | 2001-04-05 | 2001-05-23 | Merck Sharp & Dohme | Therapeutic agents |
| GB0120347D0 (en) | 2001-08-21 | 2001-10-17 | Merck Sharp & Dohme | Therapeutic agents |
| AU2002367147A1 (en) * | 2001-12-27 | 2003-07-15 | Daiichi Pharmaceutical Co., Ltd. | Beta-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS |
| GB0218041D0 (en) * | 2002-08-02 | 2002-09-11 | Merck Sharp & Dohme | Chemical process |
| GB0223039D0 (en) * | 2002-10-04 | 2002-11-13 | Merck Sharp & Dohme | Therapeutic compounds |
| GB0223038D0 (en) * | 2002-10-04 | 2002-11-13 | Merck Sharp & Dohme | Therapeutic compounds |
| DE602004011767T2 (de) | 2003-05-16 | 2009-02-19 | Merck Sharp & Dohme Ltd., Hoddesdon | Cyclohexylsulfone als gamma-sekretase-inhibitoren |
| GB0313772D0 (en) * | 2003-06-13 | 2003-07-23 | Merck Sharp & Dohme | Therapeutic treatment |
| EP1640366A4 (en) | 2003-06-30 | 2009-05-13 | Daiichi Seiyaku Co | HETEROCYCLES METHYLSULFON DERIVATIVE |
| GB0323258D0 (en) | 2003-10-04 | 2003-11-05 | Merck Sharp & Dohme | Therapeutic compounds |
| AR047666A1 (es) * | 2004-02-20 | 2006-02-01 | Merck Sharp & Dohme | Sintesis estereoselectiva del acido ciclohexanopropanoico 4,4-disubstituido |
| RU2404968C2 (ru) | 2005-04-08 | 2010-11-27 | Дайити Санкио Компани, Лимитед | Пиридилдиметилсульфоновое производное |
| ATE550019T1 (de) | 2005-05-17 | 2012-04-15 | Merck Sharp & Dohme | Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs |
| GB0513747D0 (en) * | 2005-07-06 | 2005-08-10 | Merck Sharp & Dohme | Therapeutic compounds |
| JP2009526059A (ja) | 2006-02-07 | 2009-07-16 | ワイス | １１−ベータｈｓｄ１阻害剤 |
| WO2007103114A2 (en) | 2006-03-07 | 2007-09-13 | The Brigham & Women's Hospital, Inc. | Notch inhibition in the treatment or prevention of atherosclerosis |
| US9567396B2 (en) | 2006-03-07 | 2017-02-14 | Evonik Degussa Gmbh | Notch inhibition in the prevention of vein graft failure |
| JP2010518064A (ja) | 2007-02-12 | 2010-05-27 | メルク・シャープ・エンド・ドーム・コーポレイション | Ａｄおよび関連状態の治療のためのピペラジン誘導体 |
| RU2483061C2 (ru) * | 2007-07-05 | 2013-05-27 | Шеринг Корпорейшн | Тетрагидропиранохроменовые ингибиторы гамма-секретазы |
| TW200920362A (en) | 2007-09-11 | 2009-05-16 | Daiichi Sankyo Co Ltd | Alkylsulfone derivatives |
| EP2222636B1 (en) | 2007-12-21 | 2013-04-10 | Ligand Pharmaceuticals Inc. | Selective androgen receptor modulators (sarms) and uses thereof |
| US8461389B2 (en) | 2008-04-18 | 2013-06-11 | University College Dublin, National University Of Ireland, Dublin | Psycho-pharmaceuticals |
| US8759579B2 (en) | 2008-04-23 | 2014-06-24 | Merck Sharp & Dohme Corp. | Cyclobutyl sulfones as notch sparing gamma secretase inhibitors |
| US8609897B2 (en) * | 2009-02-06 | 2013-12-17 | Merck Sharp & Dohme Corp. | Trifluoromethylsulfonamide gamma secretase inhibitor |
| EP2413932A4 (en) | 2009-04-01 | 2012-09-19 | Merck Sharp & Dohme | HAMMER OF ACT ACTIVITY |
| EP2488028B1 (en) | 2009-10-14 | 2020-08-19 | Merck Sharp & Dohme Corp. | Substituted piperidines that increase p53 activity and the uses thereof |
| EP2493497A4 (en) | 2009-11-01 | 2013-07-24 | Brigham & Womens Hospital | NOTCH INHIBITION IN THE TREATMENT AND PROPHYLAXIS OF ADIPOSITAS AND METABOLISM SYNDROME |
| EP2584903B1 (en) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| WO2012018754A2 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| HUE044815T2 (hu) | 2010-08-17 | 2019-11-28 | Sirna Therapeutics Inc | Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával |
| US8946216B2 (en) | 2010-09-01 | 2015-02-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
| US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
| EP2654748B1 (en) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
| WO2013059302A1 (en) | 2011-10-17 | 2013-04-25 | Nationwide Children's Hospital, Inc. | Products and methods for aortic abdominal aneurysm |
| EP2770987B1 (en) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| WO2013165816A2 (en) | 2012-05-02 | 2013-11-07 | Merck Sharp & Dohme Corp. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
| RU2660429C2 (ru) | 2012-09-28 | 2018-07-06 | Мерк Шарп И Доум Корп. | Новые соединения, которые являются ингибиторами erk |
| PL2925888T3 (pl) | 2012-11-28 | 2018-03-30 | Merck Sharp & Dohme Corp. | Kompozycje i sposoby do stosowania w leczeniu nowotworów |
| RU2690663C2 (ru) | 2012-12-20 | 2019-06-05 | Мерк Шарп И Доум Корп. | Замещенные имидазопиридины в качестве ингибиторов hdm2 |
| US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
| EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| JP6530764B2 (ja) * | 2014-01-06 | 2019-06-12 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ＲＯＲγ調節因子としてのピロリジニルスルホン誘導体およびその使用 |
| WO2015103510A1 (en) * | 2014-01-06 | 2015-07-09 | Bristol-Myers Squibb Company | Heterocyclic sulfone as ror-gamma modulators |
| JP6574444B2 (ja) * | 2014-01-06 | 2019-09-11 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 炭素環式スルホンＲＯＲγ調節因子 |
| WO2015104343A1 (en) * | 2014-01-09 | 2015-07-16 | Proyecto De Biomedicina Cima, S.L. | New antifibrinolytic compounds |
| US10441567B2 (en) | 2014-01-17 | 2019-10-15 | Ligand Pharmaceuticals Incorporated | Methods and compositions for modulating hormone levels |
| CA3017411C (en) | 2016-03-15 | 2024-06-25 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
| WO2018071283A1 (en) | 2016-10-12 | 2018-04-19 | Merck Sharp & Dohme Corp. | Kdm5 inhibitors |
| WO2019094312A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| EP3823672A1 (en) | 2018-07-19 | 2021-05-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Combination for treating cancer |
| WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP3833667B1 (en) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| AU2019317549A1 (en) | 2018-08-07 | 2021-02-25 | Msd International Gmbh | PRMT5 inhibitors |
| KR20220003554A (ko) | 2019-04-19 | 2022-01-10 | 리간드 파마슈티칼스 인코포레이티드 | 화합물의 결정질 형태 및 결정질 형태를 제조하는 방법 |
| CN110143935B (zh) * | 2019-06-03 | 2022-09-30 | 华侨大学 | 一种2，5-二取代呋喃衍生物的制备方法 |
| WO2021126729A1 (en) | 2019-12-17 | 2021-06-24 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP4076459A4 (en) | 2019-12-17 | 2023-12-20 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| EP4077282A4 (en) | 2019-12-17 | 2023-11-08 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| US20230416830A1 (en) | 2020-11-16 | 2023-12-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for predicting and treating uveal melanoma |
| US20240041884A1 (en) | 2020-12-07 | 2024-02-08 | Cellestia Biotech Ag | Pharmaceutical Combinations for Treating Cancer |
| EP4008324A1 (en) | 2020-12-07 | 2022-06-08 | Cellestia Biotech AG | Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer |
| TW202313020A (zh) | 2021-06-02 | 2023-04-01 | 瑞士商西萊絲蒂亞生物科技股份有限公司 | 自體免疫及發炎性疾病的治療方法 |
| WO2023079132A1 (en) | 2021-11-08 | 2023-05-11 | Cellestia Biotech Ag | Pharmaceutical combinations for treating cancer |
| EP4223292A1 (en) | 2022-02-07 | 2023-08-09 | Cellestia Biotech AG | Pharmaceutical combinations for treating cancer |
| JP2025511436A (ja) | 2022-09-02 | 2025-04-16 | メルク・シャープ・アンド・ドーム・エルエルシー | エキサテカン由来トポイソメラーゼ－１阻害薬医薬組成物及びその使用 |
| WO2024091437A1 (en) | 2022-10-25 | 2024-05-02 | Merck Sharp & Dohme Llc | Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof |
| WO2024129628A1 (en) | 2022-12-14 | 2024-06-20 | Merck Sharp & Dohme Llc | Auristatin linker-payloads, pharmaceutical compositions, and uses thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE735866C (de) * | 1941-01-17 | 1943-06-11 | Ig Farbenindustrie Ag | Verfahren zur Darstellung von Aminoalkylsulfonverbindungen |
| US2802013A (en) * | 1954-02-12 | 1957-08-06 | Searle & Co | 2-(oxo and imino)-3-(phenyl and halophenyl)-tetrahydrofuransulfones and processes for the manufacture thereof |
| US2813100A (en) * | 1955-04-26 | 1957-11-12 | Nopco Chem Co | Hydrogenation process |
| US2812330A (en) * | 1956-05-02 | 1957-11-05 | Searle & Co | Sulfone derivatives of 2, 6-piperidinedione |
| JPS5625149A (en) * | 1979-08-08 | 1981-03-10 | Sagami Chem Res Center | Keto ester derivative and its preparation |
| JPS5626847A (en) | 1979-08-13 | 1981-03-16 | Sagami Chem Res Center | Preparation of substituted salicylic acid derivative |
| JPS5626866A (en) | 1979-08-13 | 1981-03-16 | Sagami Chem Res Center | Unsaturated ketoester derivative and its preparation |
| JPH06157508A (ja) * | 1992-11-26 | 1994-06-03 | Nippon Oil & Fats Co Ltd | 新規１，３−ジチオラン誘導体、１，３−ジオキソラン誘導体及び反応性組成物 |
| US5703129A (en) * | 1996-09-30 | 1997-12-30 | Bristol-Myers Squibb Company | 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production |
| EP0863134A1 (en) * | 1997-03-07 | 1998-09-09 | Merck Frosst Canada Inc. | 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2 |
| AU773273B2 (en) | 1999-02-26 | 2004-05-20 | Bristol-Myers Squibb Company | Novel sulfonamide compounds and uses thereof |
| GB0108592D0 (en) | 2001-04-05 | 2001-05-23 | Merck Sharp & Dohme | Therapeutic agents |
| GB0108591D0 (en) | 2001-04-05 | 2001-05-23 | Merck Sharp & Dohme | Therapeutic agents |
| GB0120347D0 (en) * | 2001-08-21 | 2001-10-17 | Merck Sharp & Dohme | Therapeutic agents |
| AU2002367147A1 (en) | 2001-12-27 | 2003-07-15 | Daiichi Pharmaceutical Co., Ltd. | Beta-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS |
| DE10201392A1 (de) | 2002-01-16 | 2003-07-31 | Bayer Ag | Phenylsulfoxide und-sulfone |
| GB0218041D0 (en) | 2002-08-02 | 2002-09-11 | Merck Sharp & Dohme | Chemical process |
| GB0223040D0 (en) | 2002-10-04 | 2002-11-13 | Merck Sharp & Dohme | Therapeutic compounds |
| GB0223039D0 (en) | 2002-10-04 | 2002-11-13 | Merck Sharp & Dohme | Therapeutic compounds |
| GB0223038D0 (en) | 2002-10-04 | 2002-11-13 | Merck Sharp & Dohme | Therapeutic compounds |
| DE10254875A1 (de) | 2002-11-25 | 2004-06-03 | Bayer Healthcare Ag | Phenylsulfoxid und -sulfon-Derivate |
| GB0304524D0 (en) * | 2003-02-27 | 2003-04-02 | Merck Sharp & Dohme | Therapeutic agents |
| DE602004011767T2 (de) | 2003-05-16 | 2009-02-19 | Merck Sharp & Dohme Ltd., Hoddesdon | Cyclohexylsulfone als gamma-sekretase-inhibitoren |
| EP1640366A4 (en) | 2003-06-30 | 2009-05-13 | Daiichi Seiyaku Co | HETEROCYCLES METHYLSULFON DERIVATIVE |
| GB0323258D0 (en) * | 2003-10-04 | 2003-11-05 | Merck Sharp & Dohme | Therapeutic compounds |
-
2001
- 2001-04-05 GB GBGB0108591.9A patent/GB0108591D0/en not_active Ceased
- 2001-08-21 WO PCT/GB2001/003741 patent/WO2002081435A1/en not_active Ceased
- 2001-08-21 EP EP01958247A patent/EP1379498B1/en not_active Expired - Lifetime
- 2001-08-21 AT AT01958247T patent/ATE498608T1/de not_active IP Right Cessation
- 2001-08-21 CA CA2442882A patent/CA2442882C/en not_active Expired - Lifetime
- 2001-08-21 AU AU2001279971A patent/AU2001279971B2/en not_active Ceased
- 2001-08-21 JP JP2002579423A patent/JP5113976B2/ja not_active Expired - Fee Related
- 2001-08-21 US US10/473,727 patent/US20040116404A1/en not_active Abandoned
- 2001-08-21 DE DE60144064T patent/DE60144064D1/de not_active Expired - Lifetime
- 2001-08-21 ES ES01958247T patent/ES2359388T3/es not_active Expired - Lifetime
-
2007
- 2007-04-23 US US11/788,888 patent/US7598386B2/en not_active Expired - Lifetime
-
2008
- 2008-05-06 US US12/151,296 patent/US7595344B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004533428A5 (cg-RX-API-DMAC7.html) | ||
| JP2004531517A5 (cg-RX-API-DMAC7.html) | ||
| CA2442882A1 (en) | Sulphones which modulate the action of gamma-secretase | |
| CA2442885A1 (en) | Sulphones which modulate the action of gamma secretase | |
| BR0010366A (pt) | Composto, composição farmacêutica, método de preparar um composto, e, composto para uso em terapia | |
| JP2005501120A5 (cg-RX-API-DMAC7.html) | ||
| JP2004517843A5 (cg-RX-API-DMAC7.html) | ||
| JP2005506352A5 (cg-RX-API-DMAC7.html) | ||
| JP2001247459A5 (cg-RX-API-DMAC7.html) | ||
| NO20072515L (no) | 2-amido-4-fenyltnazolderivater, fremstilling og terapeutsik anvendelse derav | |
| RU2003120080A (ru) | Орто-замещенные азотсодержащие бисарильные соединения для применения в качестве ингибиторов калиевого канала, а также содержащие их фармацевтические композиции | |
| IN2015DN01132A (cg-RX-API-DMAC7.html) | ||
| ECSP045483A (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso | |
| RU98115659A (ru) | Сульфированные аминокислотные производные и содержащие их ингибиторы металлопротеиназ | |
| RU2006130317A (ru) | Новые, обладающие длительным действием в2-агонисты и их применение в качестве лекарственных средств | |
| RU2001135826A (ru) | Новое применение соединений в качестве антибактериальных средств | |
| JP2004534846A5 (cg-RX-API-DMAC7.html) | ||
| RU2000125568A (ru) | Производные циклоалкенов, их получение и применение | |
| RU97117350A (ru) | Ингибитор гипертрофии интимы, применение оксиндолового производного для получения ингибитора гипертрофии интимы, композиция для ингибирования гипертрофии интимы, способ предупреждения и лечения гипертрофии интимы | |
| RU99101081A (ru) | Режим введения ингибиторов н+, к+-атфазы | |
| CA2382247A1 (en) | Azaindoles having serotonin receptor affinity | |
| RU2221788C2 (ru) | Оксоциклические соединения мочевины, фармацевтическая композиция, способ лечения | |
| RU98119076A (ru) | Производные 2-(3h)-оксазолона и их применение в качестве ингибиторов сох-2 | |
| CA2612176A1 (en) | Dihydrothieno[2,3-d]pyramidine-6-carboxylic acid derivatives as pde9 inhibitors | |
| RU2002101622A (ru) | Нафтохиноновые производные и их использование для лечения и борьбы с туберкулезом |